MA33194B1 - Anticorps humanisés ayant une activité antitumorale - Google Patents

Anticorps humanisés ayant une activité antitumorale

Info

Publication number
MA33194B1
MA33194B1 MA34251A MA34251A MA33194B1 MA 33194 B1 MA33194 B1 MA 33194B1 MA 34251 A MA34251 A MA 34251A MA 34251 A MA34251 A MA 34251A MA 33194 B1 MA33194 B1 MA 33194B1
Authority
MA
Morocco
Prior art keywords
humanized antibodies
antitumor activity
colon cancer
human colon
kill
Prior art date
Application number
MA34251A
Other languages
Arabic (ar)
English (en)
Inventor
Norbert Alexander Kienzle
Adam William Clarke
Anthony Gerard Doyle
Philip Anthony Jennings
Matthew Pollard
Original Assignee
Cephalon Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009901129A external-priority patent/AU2009901129A0/en
Application filed by Cephalon Australia Pty Ltd filed Critical Cephalon Australia Pty Ltd
Publication of MA33194B1 publication Critical patent/MA33194B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des anticorps humanisés et leurs domaines de liaison ayant une activité antitumorale. En particulier, les anticorps humanisés se lient spécifiquement aux cellules tumorales du cancer du colon humain et les tuent directement. Ils présentent également une puissante activité cytotoxique à médiation immunitaire contre les cellules du cancer du colon humain
MA34251A 2009-03-16 2010-03-16 Anticorps humanisés ayant une activité antitumorale MA33194B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16068209P 2009-03-16 2009-03-16
AU2009901129A AU2009901129A0 (en) 2009-03-16 Humanised antibodies with anti-tumour activity
US25851709P 2009-11-05 2009-11-05
PCT/AU2010/000298 WO2010105290A1 (fr) 2009-03-16 2010-03-16 Anticorps humanisés ayant une activité antitumorale

Publications (1)

Publication Number Publication Date
MA33194B1 true MA33194B1 (fr) 2012-04-02

Family

ID=42739039

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34251A MA33194B1 (fr) 2009-03-16 2010-03-16 Anticorps humanisés ayant une activité antitumorale

Country Status (18)

Country Link
US (2) US8470320B2 (fr)
EP (2) EP2408820A4 (fr)
JP (1) JP5746134B2 (fr)
KR (1) KR20110129935A (fr)
CN (1) CN102395604B (fr)
AU (1) AU2010225448B2 (fr)
BR (1) BRPI1009460A2 (fr)
CA (1) CA2769276A1 (fr)
EA (1) EA024695B1 (fr)
IL (1) IL214840A (fr)
MA (1) MA33194B1 (fr)
MX (1) MX2011009704A (fr)
NZ (2) NZ600915A (fr)
SG (1) SG173577A1 (fr)
TN (1) TN2011000417A1 (fr)
UA (1) UA108349C2 (fr)
WO (1) WO2010105290A1 (fr)
ZA (1) ZA201105875B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010314798B2 (en) * 2009-11-05 2013-10-24 Teva Pharmaceuticals Australia Pty Ltd Treatment of cancer involving mutated KRAS or BRAF genes
KR102096224B1 (ko) 2011-10-28 2020-04-03 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 폴리펩티드 구축물 및 이의 용도
US9447193B2 (en) * 2013-03-24 2016-09-20 Development Center For Biotechnology Methods for suppressing cancer by inhibition of TMCC3
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
MX370377B (es) 2013-04-29 2019-12-11 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-cd38 y fusiones con interferón alfa-2b atenuado.
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
JP6730271B2 (ja) 2014-10-29 2020-07-29 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド インターフェロンα２Ｂバリアント
CN112710843B (zh) * 2020-12-16 2022-11-04 江苏伟禾生物科技有限公司 一种测定群体反应性抗体检测的板式免疫荧光试剂盒及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1071700B1 (fr) * 1998-04-20 2010-02-17 GlycArt Biotechnology AG Modification par glycosylation d'anticorps aux fins d'amelioration de la cytotoxicite cellulaire dependant des anticorps
CA2354377C (fr) * 1998-12-09 2007-04-10 Tatsuji Seki Procede de production de glycoproteines a glycosilation de type humain
EP1141024B1 (fr) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRENANT UNE VARIANTE DE LA REGION Fc DE L'IgG1 HUMAIN
EP2322644A1 (fr) 2000-06-28 2011-05-18 GlycoFi, Inc. Procédé de production de glycoprotéines modifiées
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
AU2002368077B2 (en) * 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
WO2006128690A1 (fr) * 2005-06-01 2006-12-07 Micromet Ag Anticorps anti-il2
EP1878747A1 (fr) 2006-07-11 2008-01-16 greenovation Biotech GmbH Anticorps glyco-modifiés

Also Published As

Publication number Publication date
SG173577A1 (en) 2011-09-29
AU2010225448B2 (en) 2013-10-24
US8901279B2 (en) 2014-12-02
EA024695B1 (ru) 2016-10-31
NZ600915A (en) 2013-09-27
AU2010225448A1 (en) 2011-09-08
IL214840A (en) 2015-11-30
UA108349C2 (uk) 2015-04-27
TN2011000417A1 (en) 2013-03-27
EP2408820A1 (fr) 2012-01-25
IL214840A0 (en) 2011-11-30
US20100297134A1 (en) 2010-11-25
JP2012520329A (ja) 2012-09-06
JP5746134B2 (ja) 2015-07-08
MX2011009704A (es) 2011-09-28
EA201171133A1 (ru) 2012-03-30
CN102395604B (zh) 2015-11-25
CA2769276A1 (fr) 2010-09-23
EP2408820A4 (fr) 2013-01-23
US8470320B2 (en) 2013-06-25
CN102395604A (zh) 2012-03-28
US20130280246A1 (en) 2013-10-24
ZA201105875B (en) 2012-11-28
EP2433967A2 (fr) 2012-03-28
BRPI1009460A2 (pt) 2016-03-01
KR20110129935A (ko) 2011-12-02
WO2010105290A1 (fr) 2010-09-23
NZ594668A (en) 2012-10-26
EP2433967A3 (fr) 2013-05-01

Similar Documents

Publication Publication Date Title
MA33194B1 (fr) Anticorps humanisés ayant une activité antitumorale
MX355181B (es) Anticuerpos humanos contra el factor tisular.
WO2005103081A3 (fr) Anticorps monoclonaux humains diriges contre cd20
EP4349868A3 (fr) Anticorps monoclonaux humanisés et chimériques contre cd47
WO2009083009A3 (fr) Anticorps monoclonaux anti-cd32b
WO2006099875A8 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
WO2011130434A3 (fr) Anticorps qui se lient au cd27 humain et utilisations de ceux-ci
DE602006012672D1 (de) Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen
EP3539988A3 (fr) Anticorps monoclonaux contre her2
NZ591471A (en) Antibodies to ccr2
WO2011110642A3 (fr) Anticorps monoclonaux contre c-met
WO2008112003A3 (fr) Agents liants cibles diriges contre pdgfr-alpha et utilisations associees
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
WO2011147982A3 (fr) Anticorps monoclonaux contre l'épitope de her2
NO20074063L (no) Monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA) som mangler fucosyl residier
AU2010310545A8 (en) Anti-GCC antibody molecules and related compositions and methods
PE20091342A1 (es) Inmunoglobulinas
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
EP2582722A4 (fr) Anticorps contre gd2
MX2012004084A (es) Anticuerpos siglec-15 para tratar enfermedad relacionada con perdida osea.
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
WO2010100056A3 (fr) Anticorps contre le ligand a induisant la prolifération (april)
WO2009142738A3 (fr) Compositions et procédés utilisables en matière de diagnostic et de traitement du cancer
WO2012144784A3 (fr) Anticorps monoclonaux qui reconnaissent spécifiquement la carboxylestérase 1 de foie humain, lignées cellulaires d'hybridome qui produisent les anticorps monoclonaux et leurs utilisations